Stanford researchers have found that inhibiting 15-prostaglandin dehydrogenase (15-PGDH), which breaks down prostaglandin E2 (PGE2), can improve cardiac function in diseased and aged hearts.
Stanford inventors in the Katrin Svensson laboratory have identified the protein Isthmin-1 (ISM1) as a treatment for nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH).